China begins applying Covid-19 nasal vaccine in Shanghai

Beijing, Oct 26 (Prensa Latina) China began applying in Shanghai its indigenous Covid-19 nasal vaccine, developed by the CanSino Biologics pharmaceutical company, amid recurring outbreaks caused by the Omicron strain of the SARS-CoV-2.

October 26, 2022
08:43

The drug is applied as a single-time booster dose to people previously immunized with any vaccine.

The distribution in Shanghai is taking place a month after the country’s regulators authorized the emergency use of the vaccine, the only one of its type approved so far in China, since the other 17 are intramuscular and were created using various technologies.

CanSino Biologics jointly developed the vaccine jointly with the Beijing Institute of Biotechnology, and has been conducting clinical studies since last March to confirm its safety and efficacy.

Continued Covid-19 outbreaks in China lead to putting places under different degrees of confinement and using the vaccine as an emergency measure.

At least 28,002 have died and 8,205,171 have been infected in mainland China, Hong Kong, Macao and Taiwan since the emergence of coronavirus in December 2019.

pgh/llp/oda/ymr